How Praluent Targets LDL Cholesterol
Praluent (alirocumab) is a monoclonal antibody that lowers LDL cholesterol by inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a protein produced mainly in the liver that binds to LDL receptors on liver cells, marking them for degradation. This reduces the liver's ability to pull LDL cholesterol from the blood.
By binding to PCSK9, Praluent prevents it from interacting with LDL receptors. This allows more receptors to stay on the liver surface, increasing LDL uptake and clearance from circulation. Patients typically see LDL reductions of 50-60% with every-two-week injections.[1]
What Happens in the Body Step by Step
1. Liver cells express LDL receptors to capture circulating LDL particles.
2. PCSK9 attaches to these receptors, triggering their internalization and breakdown inside the cell.
3. Fewer receptors mean less LDL removal, raising blood levels.
4. Praluent neutralizes PCSK9, preserving receptors and boosting LDL clearance by 2-3 times baseline levels.
This mechanism is distinct from statins, which reduce cholesterol synthesis in the liver.
How It Compares to Other LDL-Lowering Drugs
| Drug Class | Mechanism | LDL Reduction | Common Use Case |
|------------|-----------|---------------|-----------------|
| Praluent (PCSK9 inhibitor) | Blocks PCSK9-receptor binding | 50-70% | High-risk patients not at goal on statins |
| Statins (e.g., atorvastatin) | Inhibits HMG-CoA reductase | 20-60% | First-line for most patients |
| Evolocumab (Repatha, another PCSK9 inhibitor) | Same as Praluent | 50-70% | Similar to Praluent; head-to-head trials show near equivalence [2] |
| Ezetimibe | Blocks intestinal cholesterol absorption | 15-25% | Add-on to statins |
PCSK9 inhibitors like Praluent excel in familial hypercholesterolemia or statin-intolerant cases.
Who Benefits Most and When It's Used
Praluent is FDA-approved for adults with primary hyperlipidemia or heterozygous familial hypercholesterolemia, often alongside statins. Clinical trials (e.g., ODYSSEY) showed it cuts major cardiovascular events by 15% in high-risk groups with LDL over 70 mg/dL.[3] It's injected subcutaneously every 2-4 weeks.
Common Side Effects Patients Report
Injection-site reactions (7-10% of users), flu-like symptoms, or muscle pain occur but are usually mild. No major liver toxicity, unlike some statins. Long-term data confirm safety up to 5 years.[1]
Patent and Availability Details
Sanofi/Regeneron holds patents on Praluent through 2035 in the US (expires October 31, 2035; no Paragraph IV challenges listed).[4] Biosimilars unlikely before then.
[1]: FDA Label for Praluent
[2]: NEJM: FOURIER vs. ODYSSEY Trials
[3]: ODYSSEY Outcomes Trial
[4]: DrugPatentWatch.com - Praluent Patents